Better Context → Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
 Posted in: Glucagon, Glucose Monitoring, Insulin Delivery, Other, Topics May 07 | 2025Beta Bionics Q1 ‘25 Earnings; MetaVia Presents MASH data at EASL 2025Purchase Blast
$599
 Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other, Topics May 07 | 2025Novo Q1 ‘25 EarningsPurchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 06 | 2025Vertex, Biomea, and Esperion Q1 ‘25 Earnings; Oura Launches Glucose Feature Purchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Other, Topics May 02 | 2025FDA accepts Oral Sema NDA; Dexcom and Amgen Q1 ‘25 Earnings; Lilly Launches New Mounjaro Campaign Purchase Blast
$599
 Posted in: GLP-1RA, Other, Topics May 01 | 2025Lilly and Madrigal Q1 ’25 Earnings; Wegovy Receives Preferred Status from CVSPurchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 30 | 2025Lilly Integrates with WeightWatchers, Partners with Creyon, and Initiates New Ph3 Orfo Trials; Tandem Q1 ’25 EarningsPurchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 29 | 2025Novo Partners with Telehealth Providers; AstraZeneca, Pfizer, Novartis, and Regeneron Q1 ’25 Earnings; Abbott and Epic CGM Integration; Eversense 365 to Integrate with twiist AID SystemPurchase Blast
$599
 Posted in: GLP-1RA, Other, Topics Apr 28 | 2025Insulet Hires New CEO; Galmed Sublingual Semaglutide; Vutrisiran ATTR-CM CHMP Opinion Purchase Blast
$599
 Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 25 | 2025AbbVie Q1 ‘25 Earnings; Madrigal Hires Ex-Novartis CVRM Development LeadPurchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Apr 25 | 2025Medtronic Seeks Interoperability; Roche, Viking, Sanofi, and Merck Q1 ‘25 Earnings; Zealand Enrolls First Patient in Ph2 T2DM Study; Esperion R&D Day 2025Purchase Blast
$599
 Posted in: GLP-1RA, Other, Topics Apr 23 | 2025Lilly’s Two New Ph3 Studies in Obesity; Ascletis Ph1 Obesity Study Topline Results; Zealand Hires Ex-Lilly Exec; Lilly Sues Compounders...Again Purchase Blast
$599
 Posted in: GLP-1RA, Glucose Monitoring, Other, Topics Apr 23 | 2025Novo Files HD Oral Sema; Roche Expands US Manufacturing; MetaVia Additional Ph1 Obesity Results; Ypsomed Sells Diabetes Care Business; Biolinq $100M Series C; April CHMP Agenda Purchase Blast
$599
 Posted in: Glucose Monitoring, Insulin Delivery, Topics Apr 21 | 2025Medtronic Receives FDA Approval for Simplera + MiniMed 780GPurchase Blast
$599
 Posted in: Dual/triple agonist, GLP-1RA, Topics Apr 17 | 2025Lilly Ph3 Orforglipron T2DM Topline ResultsPurchase Blast
$599
 Posted in: Glucose Monitoring, Topics Apr 16 | 2025Abbott Q1 ’25 Earnings Update Purchase Blast
$599
 Posted in: GLP-1RA, Other, Topics Apr 15 | 2025Zealand Accelerates Hiring & Initiates New Ph2 Petrelintide Study; Merck Licenses Oral Drug Delivery Platform; MetaVia Ph1 Obesity Results; Skye Preclinical Obesity Results Purchase Blast
$599
 Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 14 | 2025Pfizer Discontinues Danuglipron in Obesity; Verve Shares Initial Ph1b HeFH/CAD Data; Novo Warns Against Counterfeit Ozempic; Syntis Announces Preliminary Data in Obesity Purchase Blast
$599
 Posted in: Glucose Monitoring, Topics Apr 10 | 2025Dexcom Receives FDA Clearance for G7 15 Day CGMPurchase Blast
$599
 Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 10 | 2025Lilly Initiates New Ph1 Eloralintide + Tirzepatide Study and DTC TV Ad; Another Integration with LillyDirect; Biophytis Confirms Ph2 Obesity Study Plans Purchase Blast
$599
 Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Apr 09 | 2025Obesity Spotlight: Roche’s Journey to Commercialization Purchase Blast
1 2 3 4 … 101

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.

Contact BradyLog In